drugset / Trial / NCT06356129

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129

Phase 3 Active not recruiting 850 enrolled Celgene Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).

Timeline

Start
2024-06-19
Primary completion
2027-08-09
Completion
2029-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Golcadomide Other / unclassified
Background Cyclophosphamide Other / unclassified
Background Doxorubicin Other / unclassified
Background Prednisone Other / unclassified
Background Rituximab Monoclonal antibody
Background Vincristine Small molecule

Indications